MVA.HIVconsv

MVA.HIVconsv is a viral vector vaccine candidate developed by the University of Oxford for the treatment and prevention of HIV-1 infection. It utilizes the Modified Vaccinia virus Ankara (MVA) platform to deliver the HIVconsv immunogen, a chimeric protein consisting of 14 highly conserved regions of the HIV-1 proteome derived from Gag, Pol, Vif, and Env proteins across Clades A, B, C, and D. The vaccine is designed to elicit robust, broad, and polyfunctional T-cell responses against these conserved regions, which are less prone to mutational escape than the hypervariable regions of the virus. In clinical development, MVA.HIVconsv is frequently evaluated in heterologous prime-boost regimens (e.g., following a DNA or simian adenovirus prime) and has been a key component of "kick and kill" strategies aimed at clearing the latent HIV reservoir in combination with latency-reversing agents like romidepsin.

Other names

Modified Vaccinia virus Ankara-HIVconsvMVA-HIVconsvHIVconsv vaccine